Viatris inc
VTRS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，股利評分優異，值得長期累積部位。若想獲得較好的進場時機，可參考技術面趨勢與波段評分
VTRS 近期報酬表現
0.52%
Viatris inc
2.06%
同產業平均
-0.34%
S&P500
與 VTRS 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
TEVA | Teva pharmaceutical industries limited | 4 分 | 5 分 | 2 分 | 3 分 | 1 分 | |
NVS | Novartis ag | 2 分 | 3 分 | 5 分 | 2 分 | 5 分 | |
AMRX | Amneal pharmaceuticals inc | 3 分 | 4 分 | 2 分 | 2 分 | 1 分 | |
RDY | Dr reddy's laboratories ltd | 4 分 | 5 分 | 5 分 | 2 分 | 3 分 | |
AMGN | Amgen inc | 3 分 | 3 分 | 5 分 | 3 分 | 5 分 |
- TEVA Teva pharmaceutical industries limited價值 4 分趨勢 5 分波段 2 分籌碼 3 分股利 1 分查看更多
VTRS 公司資訊
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Company's ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.